Volume 6.25 | Jul 3

Mammary Cell News 6.25 July 3, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
Diabolical Duo: Known Breast Cancer Gene Needs a Partner to Initiate and Spread Tumors
Researchers revealed that the gene Metadherin – which is implicated in promoting the spread of breast cancer tumors – only stimulates tumor growth when the protein made by the gene interacts with a second protein known as SND1. [Press release from Princeton University discussing online prepublication in Cancer Cell]
Press Release | Abstract | Graphical Abstract
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Exosomes from Bone Marrow Mesenchymal Stem Cells Contain a MicroRNA that Promotes Dormancy in Metastatic Breast Cancer Cells
Coculturing human breast cancer cells (BM2) with bone marrow mesenchymal stem cells (BM-MSCs) isolated from human donors revealed that BM-MSCs suppressed the proliferation of BM2 cells, decreased the abundance of stem cell-like surface markers, inhibited their invasion through Matrigel Transwells, and decreased their sensitivity to docetaxel, a common chemotherapy agent. [Sci Signal] Abstract

The E2F Transcription Factors Regulate Tumor Development and Metastasis in a Mouse Model of Metastatic Breast Cancer
Using genomic signature methods, scientists predicted a role for the activator E2F transcription factors in the MMTV-PyMT mouse model of metastatic breast cancer. [Mol Cell Biol] Abstract

The SMRT Coregulator Enhances Growth of Estrogen Receptor-α-Positive Breast Cancer Cells by Promotion of Cell Cycle Progression and Inhibition of Apoptosis
Small-interfering RNA and short-hairpin RNA approaches were used to determine the effects of SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) depletion on growth of estrogen receptor-α (ERα)-positive MCF-7 and ZR-75-1 breast cancer cells, as well as the ERα-negative MDA-MB-231 breast cancer line. [Endocrinology] Abstract

Estrogen Regulation of Anti-Apoptotic Bcl-2 Family Member Mcl-1 Expression in Breast Cancer Cells
In estrogen receptor-α (ERα) positive cell lines MCF-7 and ZR-75, estrogen treatment increased Mcl-1 expression at both the protein and mRNA level. In two ERα negative cell lines, SK-BR-3 and MDA-MB-231, estrogen failed to increase in Mcl-1 protein expression. [PLoS One] Full Article

CD24 Regulates Stemness and the Epithelial to Mesenchymal Transition through Modulation of Notch1 mRNA Stability by p38MAPK
Researchers report that CD24 knockdown resulted in decreased expression of Notch1 in MCF-7 cells. CD24-downstream p38MAPK was shown to regulate Notch1 at the level of mRNA stability. They also found that CD24-mediated cell migration, invasion, mammosphere formation, and drug resistance was regulated by its downstream target Notch1. [Arch Biochem Biophys] Abstract

Matrix Metalloproteinase 1 and Circulating Tumor Cells in Early Breast Cancer
Researchers assessed the correlation between circulating tumor cells and tumor matrix metalloproteinases in breast cancer. They studied 149 primary breast cancer patients treated by surgery. [BMC Cancer] Full Article

Perfluorooctanoic Acid Stimulates Breast Cancer Cells Invasion and Up-Regulates Matrix Metalloproteinase-2/-9 Expression Mediated by Activating NF-κB
Scientists explored the molecular mechanisms undergoing the stimulation effects of perfluorooctanoic acid (PFOA) on cancer cell invasion and matrix metalloproteinases expression. Trans-well filter assay showed that PFOA exposure (≥5 nM) evidently enhanced the invasion ability of the breast cancer cells MDA-MB-231. [Toxicol Lett] Abstract

Formononetin Inhibits Migration and Invasion of MDA-MB-231 and 4T1 Breast Cancer Cells by Suppressing MMP-2 and MMP-9 through PI3K/AKT Signaling Pathways
Researchers examined the effect of formononetin on the migration and invasion of breast cancer cells MDA-MB-231 and 4T1 in vitro and in vivo. Results suggest that formononetin inhibited breast cancer cell migration and invasion by reducing the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 through the PI3K/AKT signaling pathway. [Horm Metab Res] Abstract

CLINICAL RESEARCH

Improved Overall Survival after Contralateral Risk-Reducing Mastectomy in BRCA1/2 Mutation Carriers with a History of Unilateral Breast Cancer: A Prospective Analysis
Researchers examined the efficacy of contralateral risk-reducing mastectomy on overall survival in mutation carriers with a history of primary breast cancer. [Int J Cancer] Abstract

Efficacy of Six Month Neoadjuvant Endocrine Therapy in Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients – A Phase II Trial
Investigators present the outcomes of the TEAM IIA trial, a multicenter, Phase II trial investigating the efficacy of six months of neoadjuvant exemestane in postmenopausal, strong estrogen receptor-positive breast cancer patients. [Eur J Cancer] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
Non-Conventional Functions for NF-κB Members: The Dark Side of NF-κB
The authors discuss the principal non-conventional functions that have been identified for specific NF-κB elements, how they connect with other signaling pathways and their potential impact on cancer. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
Genentech announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. With this acquisition, Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders for the potential treatment of hormone receptor-positive breast cancer. [Genentech, Inc.] Press Release

First Breast Cancer Cell Bank in Singapore
A breast cancer cell bank has been set up in Singapore for the first time to help develop better understanding of and treatments for tumors. [National University of Singapore] Press Release

Licensing Agreement to Develop Stem Cell Based Breast Cancer Diagnostic
Tiziana Life Sciences announced that it has entered into an exclusive license agreement with TTFactor S.r.l. covering the use of twenty defined stem cell markers for patient stratification in breast cancer. [Tiziana Life Sciences PLC] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Case Western Reserve Cancer Stem Cell Conference
August 17-20, 2014
Cleveland, United States

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

Postdoctoral Fellow – Breast Cancer Biology (University of Tennessee Health Science Center)

PhD Candidate – ECM Proteins in Breast Cancer Progression and Metastasis (Norwegian University of Science and Technology)

Postdoctoral Associates – Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Candidates – Cell Biology (Albert Einstein College of Medicine)

PhD Research Fellow – Molecular Cancer Research (Norwegian University of Science and Technology)

Postdoctoral Fellow – Tumor Microenvironment of Bone Metastasis of Breast and Prostate Cancer (University of Edinburgh)

Postdoctoral Scholar – Cancer and RNA Research (Northwestern University)

Postdoctoral Research Associates – Pattern Formation during Branching Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us